Carregant...
Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis
OBJECTIVE: Novel treatments such as natalizumab and fingolimod achieve their therapeutic efficacy in multiple sclerosis (MS) by blocking access of subsets of immune cells into the central nervous system, thus creating nonphysiological intrathecal immunity. In contrast, daclizumab, a humanized monocl...
Guardat en:
| Publicat a: | Ann Clin Transl Neurol |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BlackWell Publishing Ltd
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4435700/ https://ncbi.nlm.nih.gov/pubmed/26000318 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/acn3.181 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|